AR035219A1 - Compuesto de 1, 2, 3, 4, 4a, 5, 6, 7, 8, 8 a-decahidroisoquinolina, su uso para preparar una composicion farmaceutica, dicha composicion farmaceutica y procedimiento para preparar dicho compuesto - Google Patents

Compuesto de 1, 2, 3, 4, 4a, 5, 6, 7, 8, 8 a-decahidroisoquinolina, su uso para preparar una composicion farmaceutica, dicha composicion farmaceutica y procedimiento para preparar dicho compuesto

Info

Publication number
AR035219A1
AR035219A1 ARP020100031A ARP020100031A AR035219A1 AR 035219 A1 AR035219 A1 AR 035219A1 AR P020100031 A ARP020100031 A AR P020100031A AR P020100031 A ARP020100031 A AR P020100031A AR 035219 A1 AR035219 A1 AR 035219A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
co2h
formula
compound
Prior art date
Application number
ARP020100031A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR035219A1 publication Critical patent/AR035219A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto de fórmula (1) en donde Z representa un átomo de azufre u oxígeno; R1 representa hidrógeno, CN, alquilo (C1-4)-CO2H, CO2H o tetrazolo; R2 representa hidrógeno, halo, arilo, arilo sustituido, CO2H, tetrazolo, alquilo C1-4, alquilarilo C1-4, heterociclo, heterociclo sustituido, CF3, NHR3, o -OR4; R3 representa hidrógeno, alquilo C1-4, alquilarilo (C1-4) o arilo; R4 representa alquilo (C1-6), alquilarilo (C1-4), alquilo (C1-4)-heterociclo, alquilo(C1-4)cicloalquilo(C3-10, alquilo(C1-4)(arilo(sustituido), arilo o heterociclo; y W, X e Y cada uno independientemente representa hidrógeno, halo, alquilo (C1-6), alcoxi (C1-4), arilo, arilo sustituido, CO2H, CO(NH2), CF3, NH-arilo, NH2, o NO2, u opcionalmente X y R2 conjuntamente, o W y X juntos, o Y y R2 juntos, conjuntamente con los átomos de carbono a los cuales se encuentran fijados, forman un grupo benzo-fusionado; con la condición de que cuando Z es azufre, entonces R1 es hidrógeno, CO2H, o tetrazolo, R2 es hidrógeno, halo, alquilo (C1-4), o CO2H, y W, X e Y son cada uno hidrógeno, halo(C1-6)alquilo, CO2H o CN(NH2); o una sal farmacéuticamente aceptable o prodroga del mismo. En otra realización, se provee el uso de dicho compuesto de fórmula (1) para la preparación de una composición farmacéutica de utilidad en un método para tratar o prevenir una enfermedad neurológica, o estado neurodegenerativo, que comprende administrar a un paciente que lo necesite una cantidad efectiva de un compuesto de la Fórmula (1) o una sal farmacéuticamente aceptable o prodroga del mismo. En forma más específica, dicho compuesto de fórmula (1) o una sal farmacéuticamente aceptable o prodroga del mismo, es de utilidad para tratar o prevenir dolor o migrana. Además se proveen composiciones farmacéuticas de compuestos de la fórmula (1), incluyendo las sales farmacéuticamente aceptables, prodrogas e hidratos del mismo, que comprenden, un compuesto de la fórmula (1) en combinación con un vehículo farmacéuticamente aceptable, diluyente o excipiente. Se proveen también intermediarios y procedimientos para la síntesis de los compuestos de la fórmula (1).
ARP020100031A 2001-01-05 2002-01-04 Compuesto de 1, 2, 3, 4, 4a, 5, 6, 7, 8, 8 a-decahidroisoquinolina, su uso para preparar una composicion farmaceutica, dicha composicion farmaceutica y procedimiento para preparar dicho compuesto AR035219A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01500004 2001-01-05

Publications (1)

Publication Number Publication Date
AR035219A1 true AR035219A1 (es) 2004-05-05

Family

ID=8183456

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100031A AR035219A1 (es) 2001-01-05 2002-01-04 Compuesto de 1, 2, 3, 4, 4a, 5, 6, 7, 8, 8 a-decahidroisoquinolina, su uso para preparar una composicion farmaceutica, dicha composicion farmaceutica y procedimiento para preparar dicho compuesto

Country Status (16)

Country Link
EP (2) EP1368032B1 (es)
JP (2) JP4132049B2 (es)
CN (1) CN100548299C (es)
AR (1) AR035219A1 (es)
AT (1) ATE397931T1 (es)
AU (1) AU2001298028B8 (es)
BR (1) BR0116724A (es)
CA (1) CA2432464C (es)
CY (1) CY1108259T1 (es)
DE (1) DE60134427D1 (es)
DK (1) DK1368032T3 (es)
ES (1) ES2306690T3 (es)
MX (1) MXPA03005982A (es)
PE (1) PE20020842A1 (es)
PT (1) PT1368032E (es)
WO (1) WO2003024453A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005529892A (ja) 2002-04-26 2005-10-06 イーライ・リリー・アンド・カンパニー 鎮痛剤としてのデカヒドロイソキノリン−３−カルボン酸のエステルプロドラッグ
CN116332807A (zh) * 2023-03-24 2023-06-27 安徽秀朗新材料科技有限公司 一种3-（三氟甲基磺酰基）-2-萘甲酸甲酯的生产工艺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5446051A (en) * 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
CA2285192A1 (en) * 1997-04-07 1998-10-15 Smriti Iyengar Pharmacological agents
IL146697A0 (en) * 1999-07-06 2002-07-25 Lilly Co Eli SELECTIVE iGluR5 RECEPTOR FOR THE TREATMENT OF MIGRAINE
AU2574801A (en) * 1999-12-22 2001-07-03 Eli Lilly And Company Selective iGLUR5 receptor antagonists

Also Published As

Publication number Publication date
AU2001298028B8 (en) 2006-08-10
EP1368032A1 (en) 2003-12-10
CA2432464C (en) 2011-07-19
JP2008179650A (ja) 2008-08-07
JP4132049B2 (ja) 2008-08-13
MXPA03005982A (es) 2003-09-10
ES2306690T3 (es) 2008-11-16
CA2432464A1 (en) 2003-03-27
JP2004522804A (ja) 2004-07-29
CN1856308A (zh) 2006-11-01
DE60134427D1 (de) 2008-07-24
PE20020842A1 (es) 2002-09-21
AU2001298028B2 (en) 2006-07-13
WO2003024453A1 (en) 2003-03-27
CN100548299C (zh) 2009-10-14
DK1368032T3 (da) 2008-09-29
PT1368032E (pt) 2008-09-04
EP1368032B1 (en) 2008-06-11
BR0116724A (pt) 2004-01-27
CY1108259T1 (el) 2014-02-12
ATE397931T1 (de) 2008-07-15
EP2166003A1 (en) 2010-03-24

Similar Documents

Publication Publication Date Title
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR037329A1 (es) Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos
AR035069A1 (es) Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
AR045551A1 (es) Compuestos fenil o piridil amida como prostaglandina e2 antagonistas
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
AR033525A1 (es) Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento
AR038686A1 (es) Formulaciones de derivados de androstano y agonistas del adrenoreceptor beta 2 antiinflamatorios
AR067575A1 (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
EA200500846A1 (ru) Замещенные арилтиомочевины и родственные соединения; ингибиторы вирусной репликации
AR035612A1 (es) 4-(piperidin-4-ilmetil)benzamidas, o sus sales, esteres o solvatos, composiciones farmaceuticas que los comprenden, usos de los mismos para preparar medicamentos, y un kit para utilizar en el tratamiento de una enfermedad cognitiva o neurodegenerativa
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
AR057835A1 (es) Derivados de 9- azabiciclo (3.3.1)nonano y composicion farmaceutica
AR029373A1 (es) Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas
UY27979A1 (es) Indoles sustituidos en posición 2,4
BR0008321A (pt) Secretagogos de hormÈnio de crescimento
RU2007141412A (ru) Пиридилдиметилсульфоновое производное
DK1412332T3 (da) Quinolinderivater og anvendelse deraf som antitumormidler
AR035219A1 (es) Compuesto de 1, 2, 3, 4, 4a, 5, 6, 7, 8, 8 a-decahidroisoquinolina, su uso para preparar una composicion farmaceutica, dicha composicion farmaceutica y procedimiento para preparar dicho compuesto
AR044014A1 (es) Composiciones farmaceuticas para administracion intranasal de acido [2-(8,9-dioxo-2, 6-diazabiciclo [5.2.0) non-1 (7) -en-2-il)alquil]-fosfonico y derivados y metodos de utilizacion de las mismas
CA1327163C (en) Anxiolytically active piperazine derivatives
AR040240A1 (es) Derivados de acido 3-mercaptopentanoico 2.5-disustituido
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas
ATE172959T1 (de) Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten

Legal Events

Date Code Title Description
FG Grant, registration